Drug Profile


Alternative Names: Belmalip; Colemin; Denan; L-644128-000U; Lipex; Liponorm; Lipovas; Lodales; Medipo; MK-733; Pantok; Sinvacor; Sivastin; Synvinolin; Velastatin; Zocor; Zocord

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medical University of South Carolina; Merck Sharp & Dohme
  • Developer Cystic Fibrosis Foundation Therapeutics; Medical University of South Carolina; Merck & Co; Merck Sharp & Dohme; Sahlgrenska University Hospital; University of Tokyo
  • Class Antihyperlipidaemics; Naphthalenes; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic cardiomyopathy; Hypercholesterolaemia; Hyperlipoproteinaemias; Hypertriglyceridaemia; Low HDL cholesterol
  • Phase I Cystic fibrosis
  • No development reported Multiple sclerosis
  • Discontinued Alzheimer's disease; Bone resorption; Rheumatoid arthritis

Most Recent Events

  • 01 Mar 2017 University College London initiates the phase III MS-STAT2 trial for Multiple sclerosis in United Kingdom
  • 15 Mar 2016 Biomarkers information updated
  • 08 Jun 2011 The FDA announces labelling changes for high-dose simvastatin (80mg) for the treatment of Hypercholesterolaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top